Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited has announced a board meeting scheduled for August 18, 2025, to approve the publication of its unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting could impact the company’s financial strategy and shareholder returns, reflecting its ongoing operational and financial planning.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands with limited liability, focusing on the biopharmaceutical industry. It is listed on the Hong Kong Stock Exchange under the stock code 1177.
Average Trading Volume: 165,077,050
Technical Sentiment Signal: Buy
Current Market Cap: HK$134.5B
See more data about 1177 stock on TipRanks’ Stock Analysis page.